Incyte Corp v. Alkem Laboratories Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Incyte Corporation and Incyte Holdings Corporation (Delaware)
  • Defendant: Alkem Laboratories Ltd. (India) and Ascend Laboratories, LLC (New Jersey)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 1:26-cv-02338, D.N.J., 03/05/2026
• Venue Allegations: Venue for Alkem Laboratories Ltd. is alleged to be proper as it is a foreign corporation that may be sued in any judicial district. Venue for Ascend Laboratories, LLC is alleged to be proper based on its incorporation in New Jersey and its regular and established place of business in the district.
• Core Dispute: Plaintiff alleges that Defendants' Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of the drug Jakafi® (ruxolitinib) constitutes an act of infringement of three patents related to specific salt forms of the ruxolitinib compound.
• Technical Context: The technology concerns specific salt formulations of ruxolitinib, an inhibitor of Janus kinases (JAKs) used for treating myeloproliferative neoplasms (a group of blood cancers) and other conditions.
• Key Procedural History: This action arises under the Hatch-Waxman Act, triggered by Defendant Alkem's submission of ANDA No. 221191 to the FDA with a Paragraph IV Certification, alleging that Plaintiff's patents are invalid and/or will not be infringed by the proposed generic products.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,722,693 - Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

The Invention Explained

• Problem Addressed: The patent background section notes a continual need for "new or improved forms of existing Janus kinase inhibitors" for developing "new, improved, and more effective pharmaceutical formulations" '693 Patent, col. 2:20-25 This suggests that the previously known free base form of the active compound may have had suboptimal properties for pharmaceutical development, such as poor solubility, stability, or manufacturing characteristics.
• The Patented Solution: The invention provides specific salt forms of the ruxolitinib molecule, including maleic, sulfuric, and phosphoric acid salts '693 Patent, col. 2:58-64 These salts are described as having advantageous properties over the free base, including high crystallinity, which can facilitate pharmaceutical formulation and improve handling, stability, and storage '693 Patent, col. 3:1-7
• Technical Importance: The selection of an appropriate salt form is a critical step in drug development, as it directly impacts a drug's physical and chemical properties, influencing its bioavailability, manufacturability, and shelf life.

Key Claims at a Glance

• The complaint does not identify specific claims but alleges infringement of "one or more claims" of the patent Compl. ¶37 Independent claim 1 is a composition of matter claim.
• Independent Claim 1 Elements:
  • A (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt.

U.S. Patent No. 8,822,481 - Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

The Invention Explained

• Problem Addressed: Similar to the '693 Patent, the background of the '481 Patent describes a need for improved forms of existing Janus kinase inhibitors to enable the development of more effective pharmaceutical formulations '481 Patent, col. 2:20-25
• The Patented Solution: The patent claims methods of using specific salt forms of ruxolitinib, particularly the phosphoric acid salt, to inhibit the activity of JAK1 and/or JAK2 enzymes '481 Patent, col. 12:21-29 The salt forms provide advantageous properties, such as improved stability and solubility, making them suitable for administration to a patient '481 Patent, col. 3:1-7
• Technical Importance: This patent extends protection from the chemical composition itself to the therapeutic method of using that specific, improved salt form to achieve a biological effect (JAK inhibition) in a patient.

Key Claims at a Glance

• The complaint does not identify specific claims but alleges infringement of "one or more of the claims" of the patent Compl. ¶46 Independent claim 1 is a method of use claim.
• Independent Claim 1 Elements:
  • A method of inhibiting JAK1 and/or JAK2 in a patient in need thereof,
  • comprising administering to said patient an effective amount of a compound that is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt.

U.S. Patent No. 8,829,013 - Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

• Technology Synopsis: The patent claims methods of treating specific diseases by administering the phosphoric acid salt of ruxolitinib '013 Patent, col. 12:22-30 Like its related patents, the '013 Patent relies on the improved pharmaceutical properties of the salt form to enable its use in a therapeutic context for treating myeloproliferative disorders '013 Patent, col. 3:1-7
• Asserted Claims: The complaint alleges infringement of "one or more claims" of the patent Compl. ¶55 Independent claim 1 is a method of treatment claim.
• Accused Features: The accused feature is Defendant Alkem's proposed generic ruxolitinib product, for which it submitted ANDA No. 221191 to the FDA seeking marketing approval Compl. ¶1 Compl. ¶55

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are "Alkem's Proposed Products," which are the proposed generic versions of Incyte's Jakafi® (ruxolitinib) drug product in 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg tablet forms, as described in ANDA No. 221191 Compl. ¶1 Compl. ¶18 Compl. ¶31

Functionality and Market Context

As a proposed generic drug, the functionality of Alkem's product is intended to be bioequivalent to the branded Jakafi® product, which functions as a Janus kinase (JAK) inhibitor Compl. ¶1 The complaint alleges that Defendants seek to manufacture, market, and sell these generic products in the United States prior to the expiration of the patents-in-suit, positioning them as direct competitors to Plaintiff's branded drug Compl. ¶1 Compl. ¶35 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a claim chart or detailed, element-by-element infringement allegations. The infringement counts are based on the legal premise that the submission of ANDA No. 221191 with a Paragraph IV certification is a technical act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶37 Compl. ¶46 Compl. ¶55 As such, a claim chart summary cannot be constructed from the complaint's allegations.

• Identified Points of Contention:
  • For the '693 Patent (Composition Claim): A primary point of contention will likely be a factual question of chemical identity. The dispute may center on whether the active pharmaceutical ingredient in Alkem's proposed product is, in fact, the specific phosphoric acid salt claimed in the patent. This could raise questions regarding the salt's stoichiometry, hydration state, or crystalline form (polymorphism), and whether those characteristics fall within the scope of the asserted claims as construed by the court.
  • For the '481 and '013 Patents (Method Claims): A central issue will be induced infringement. The analysis will focus on whether the proposed prescribing information for Alkem's generic product instructs or encourages physicians and patients to administer the drug in a manner that performs the claimed methods (i.e., inhibiting JAK1/JAK2 or treating a myeloproliferative disorder). The complaint alleges that the proposed label will be "similar to that for Jakafi®" and will instruct users to perform the claimed methods Compl. ¶33 A point of contention may be whether the language in the proposed label meets the specific limitations of the claims and whether Plaintiff can establish Defendants' specific intent to induce infringement.

V. Key Claim Terms for Construction

• The Term: "phosphoric acid salt" (from '693 Patent, Claim 1)

• Context and Importance: This term defines the entire scope of the composition claim. Its construction is critical because Defendants may argue that their proposed product, while containing ruxolitinib and a phosphate counter-ion, is a different "salt" (e.g., a different polymorphic form, a co-crystal, or a salt with a different stoichiometric ratio) that falls outside the claim's scope.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The plain language of claim 1 itself does not specify a particular crystalline form or stoichiometric ratio, which may support a construction covering any substance formed by the acid-base reaction between ruxolitinib and phosphoric acid.
  • Evidence for a Narrower Interpretation: The specification emphasizes that the disclosed salts were "highly crystalline" '693 Patent, col. 3:1-2, and Example 2 details the preparation of what appears to be a 1:1 salt '693 Patent, col. 11:12-25 A defendant could argue that the claims should be limited to the specific crystalline 1:1 salt form disclosed and enabled in the specification, particularly in view of dependent claims that explicitly recite a "crystalline" salt (e.g.,'693 Patent, claim 5).

• The Term: "inhibiting" (from '481 Patent, Claim 1)

• Context and Importance: This term defines the functional outcome of the claimed method. A dispute could arise over the degree or type of enzymatic inhibition required to meet this limitation. Practitioners may focus on this term because a defendant could argue that while its product has a therapeutic effect, the mechanism or degree of JAK inhibition does not meet the standard of "inhibiting" as understood in the context of the patent.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The patent broadly links JAK activity to numerous diseases, including immune disorders, skin disorders, and cancer '481 Patent, col. 4:16-62 This could support a view that any administration for these conditions that produces a therapeutic effect necessarily involves "inhibiting" the target enzyme.
  • Evidence for a Narrower Interpretation: Example A of the patent describes a specific in vitro kinase assay used to measure the IC50 value, a quantitative measure of inhibition '481 Patent, col. 11:54 - col. 12:21 A party could argue that "inhibiting" should be construed to require a specific, measurable level of potency or reduction in enzyme activity, as characterized by the assays disclosed in the specification.

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement for all three patents-in-suit. The inducement allegation is based on the claim that Defendants' proposed product labeling will instruct and encourage medical professionals and patients to use the generic drug in accordance with the patented methods Compl. ¶40 Compl. ¶49 Compl. ¶58 The contributory infringement allegation is based on the claim that Defendants' product is especially adapted for an infringing use and has no substantial non-infringing use Compl. ¶41 Compl. ¶50 Compl. ¶59
• Willful Infringement: The complaint does not use the term "willful," but it alleges that the case is "exceptional" and requests an award of attorneys' fees under 35 U.S.C. § 285 Compl. ¶44 Compl. ¶53 Compl. ¶62 The basis for this claim appears to be Defendants' pre-suit knowledge of the patents, evidenced by Alkem's submission of a Paragraph IV Certification to the FDA and its subsequent written notice to Incyte Compl. ¶34 Compl. ¶35

VII. Analyst's Conclusion: Key Questions for the Case

1. A central issue will be one of chemical identity: does the active pharmaceutical ingredient in Alkem's proposed generic product meet all the limitations of the asserted composition claims, particularly with respect to physical form (e.g., crystallinity, polymorphism) which may be incorporated into the claims during claim construction?
2. A key legal question will be one of induced infringement: will the final, FDA-approved label for Alkem's generic product contain instructions that directly correspond to the methods claimed in the '481 and '013 patents, and can Incyte provide sufficient evidence of Alkem's specific intent to encourage infringement by third parties?
3. A determinative issue, prompted by the defendants' Paragraph IV certification, will be one of validity: do the claimed salt forms of ruxolitinib exhibit unexpected and advantageous properties over the prior art free base, sufficient to render the claims non-obvious, or are they merely an obvious and routine selection of a common pharmaceutical salt?